(Q84543964)

English

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial

scientific article published on 01 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

0 references

(RS)-rosiglitazone

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Dawn M Torres

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Frances J Jones

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Janet C Shaw

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Christopher D Williams

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

John A Ward

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Stephen A Harrison

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

0 references

publication date

1 November 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

54

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1631-1639

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Lifestyle modification as the primary treatment of NASH.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Revisiting the rosiglitazone story--lessons learned

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24558

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.24558

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21748770%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84543964&oldid=2128059612"